The current position of precuffed expanded polytetrafluoroethylene bypass grafts in peripheral vascular surgery

Slegt, Jasper van der; Steunenberg, Stijn L.; Donker, Jeroen M.W.; Veen, Eelco J.; Ho, Gwan H.; Groot, Hans G.W. de; Laan, Lijckle van der

doi:10.1016/j.jvs.2014.01.062

Cited by 27 publications

(17 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…30 Delirium In our hospital, several studies before implementation of the DHPSP have been performed. A study by van der Slegt et al 31 reported a delirium incidence of 3% in patients receiving peripheral vascular surgery. This study, performed in 2012, reported a lower incidence rate on delirium compared with this study.…”

Section: Discussionmentioning

confidence: 99%

Current Factors of Fragility and Delirium in Vascular Surgery

Raats

Lepper

Feitsma

et al. 2015

Annals of Vascular Surgery

Self Cite

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Current Factors of Fragility and Delirium in Vascular Surgery

Raats

Lepper

Feitsma

et al. 2015

Annals of Vascular Surgery

Self Cite

View full text Add to dashboard Cite

“…In this report, we demonstrate the effectiveness of SLIPS-modified biomedical implants to resist device-associated infection after bacterial challenge in vivo. Expanded polytetrafluoroethylene (ePTFE) was selected as a model material given its prevalent use in clinical care in the form of prosthetic hernia meshes [36-38], grafts for cardiovascular reconstruction [39, 40], and as alloplastic implants in cosmetic and reconstructive surgery [41-43], as well as its known susceptibility to infection [44, 45]. As a porous, fluorinated implant material, ePTFE is readily amenable to infusion with fluorinated lubricants, such as perfluoropolyether (PFPE), perfluoroperhydrophenanthrene (PFPH), and perfluorodecalin (PFD).…”

Section: Introductionmentioning

confidence: 99%

An immobilized liquid interface prevents device associated bacterial infection in vivo

et al. 2017

View full text Add to dashboard Cite

Virtually all biomaterials are susceptible to biofilm formation and, as a consequence, device-associated infection. The concept of an immobilized liquid surface, termed slippery liquid-infused porous surfaces (SLIPS), represents a new framework for creating a stable, dynamic, omniphobic surface that displays ultralow adhesion and limits bacterial biofilm formation. A widely used biomaterial in clinical care, expanded polytetrafluoroethylene (ePTFE), infused with various perfluorocarbon liquids generated SLIPS surfaces that exhibited a 99% reduction in S. aureus adhesion with preservation of macrophage viability, phagocytosis, and bactericidal function. Notably, SLIPS modification of ePTFE prevents device infection after S. aureus challenge in vivo, while eliciting a significantly attenuated innate immune response. SLIPS-modified implants also decrease macrophage inflammatory cytokine expression in vitro, which likely contributed to the presence of a thinner fibrous capsule in the absence of bacterial challenge. SLIPS is an easily implementable technology that provides a promising approach to substantially reduce the risk of device infection and associated patient morbidity, as well as health care costs.

show abstract

“…During the 5-year follow-up, the patency rate with ASV was better than with PTFE grafts (82% vs. 26%, p<0.05). 6 ) Surgical bypass with PTFE should therefore be limited to patients with no other revascularization option. Meanwhile, the operative mortality is highly variable, which can range from 1.3% to 6.3%, which largely depends on cardiovascular risk, and should be considered preoperatively.…”

mentioning

confidence: 99%

When Are Endovascular and Open Bypass Treatments Preferred for Femoropopliteal Occlusive Disease?

AbuRahma

2018

Annals of Vascular Diseases

View full text Add to dashboard Cite

Several meta-analyses and multicenter trials have shown that chronic limb ischemia did not occur for up to 5 years in 50%–70% of patients who underwent saphenous vein grafts, with limb salvage and perioperative mortality rates of >80% and 3%, respectively. However, open surgical bypass can have limitations, including postoperative morbidity/wound complications of 10%–20% and prolonged length of hospital stay and outpatient care. Several studies have analyzed clinical outcomes for patients with critical limb ischemia treated with endovascular therapies, but they have been mainly retrospective with significant heterogeneity or were single center. Only few randomized trials have compared surgical vs. endovascular therapy. These included the Bypass vs. Angioplasty in Severe Ischemia of the Leg (BASIL) trial, with no differences found in amputation-free or overall survival rates at 1 year; however, late outcomes favored the surgical group. The Bypass or Angioplasty in Severe Intermittent Claudication (BASIC) trial concluded that the 1-year patency rates were 82% and 43% for bypass and angioplasty, respectively. The BEST Endovascular vs. Best Surgical Therapy in Patients with Critical Limb Ischemia (BEST-CLI) trial is currently enrolling patients. This review analyzed studies comparing open vs. endovascular therapy in patients with femoropopliteal disease. (This is a review article based on the invited lecture of the 45th Annual Meeting of Japanese Society for Vascular Surgery.)

show abstract

The current position of precuffed expanded polytetrafluoroethylene bypass grafts in peripheral vascular surgery

Abstract: ASV bypasses are still the first-choice conduit in peripheral bypass surgery performed in patients with PAD. Precuffed ePTFE bypasses are acceptable alternatives in the absence of adequate autologous vein.

Cited by 27 publications

References 24 publications

Current Factors of Fragility and Delirium in Vascular Surgery

Current Factors of Fragility and Delirium in Vascular Surgery

An immobilized liquid interface prevents device associated bacterial infection in vivo

When Are Endovascular and Open Bypass Treatments Preferred for Femoropopliteal Occlusive Disease?

Contact Info

Product

Resources

About